This animation visualizes the mini-protoplast containing the concentrated protein production machinery of the living cell.
We offer an end-to-end protein service for research-grade protein expression. From cloning to expression and purification, we enable our customers to unlock new potential for their research projects, without occupying their own resources.
ALiCE is available as a protein expression kit in three different sizes for small-scale protein expression for research purposes.
Interested in producing your protein of interest in large amounts? Contact our sales team.
We believe that everyone deserves an equal chance to lead a healthy life.
That's why we created ALiCE, a disruptive cell-free protein technology that will change the way proteins are produced.
Our goal? To simplify biomanufacturing and speed up the delivery of drugs to the patient.
A therapeutic target like no other
With unmatched therapeutic potential, GPCRs account for ~35% of FDA-approved drugs, achieving the status of the most common class of therapeutic target. They also happen to be one of the most challenging classes of protein to express. In this case study, we explore the rapid expression and in-lysate functional analysis of the CB2 GPCR using the ALiCE® expression system.
Plant-based ALiCE technology could shave weeks off vaccine production
LenioBio has received CEPI (Coalition for Epidemic Preparedness Innovations) funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days.
Scaling eukaryotic cell-free protein synthesis
In our latest publication in the Journal of Biotechnology and Bioengineering, we describe the production and functional analysis of complex proteins using ALiCE, and showcase scaling in the system – a first for eukaryotic cell-free.
Why your membrane protein expression might be failing, and how to rescue it
Challenging to express, membrane proteins exhibit instability, low yields, and aggregation issues. Optimizing expression is essential from target characterization to clinical candidate selection. In this article, we address potential expression failures and strategies to overcome them.
LenioBio GmbH
Erkrather Str. 401 , 40231 Düsseldorf
c/o Fraunhofer IME Building
Forckenbeck Str. 6, 52074 Aachen